Adverum Biotechnologies Inc. - ADVM Enterprise Value-to-Revenue Multiple

Adverum Biotechnologies (ADVM) - corporate logo

A high barrier to entry in ophthalmological gene therapy is maintained by complex patents and scientific exclusivity. The price-to-sales dynamics of Adverum Biotechnologies (ADVM) demonstrate the current market consensus, where the value 0.00 reflects the metric's balance. The business relies on external contractors for vector production, while the implementation of the Ixo-vec drug ensures lifelong patient adherence to FDA-controlled clinics.

Adverum Biotechnologies - ADVM Company Value to Revenue (period 11/23/2025 - 12/20/2025)

Financial and market metric breakdowns for Adverum Biotechnologies, Inc. (ADVM)

- share price and expert price forecast:
- cash and cash flow indicators:
Fundamental company valuation:Adverum Biotechnologies Inc. - ADVM
Manufactured product of adverum.com

To build a high-quality portfolio, I utilize EV/Sales, which compares the total enterprise value of a business to its revenue, excluding the impact of debt to determine the asset's fair value. In the case of Adverum Biotechnologies (ADVM), this calculation reflects the market valuation of the ophthalmologists' intellectual capital and gene therapy costs; therefore, analyzing the EV/Sales multiple allows for the timely detection of an overvaluation of R&D potential.